Oral levofloxacin in the treatment of community-acquired pneumonia.
We evaluated the efficacy of oral levofloxacin (500mg/day for 7-21 days) in the treatment of 20 adults patients with community-acquired pneumonia (CAP) requiring hospitalization in an open prospective study. The microbiological cause of the pneumonia was identified in 14/20 patients using lower respiratory tract secretions obtained by bronchoscopy (12) and/or blood culture (2). Eight patients had S. pneumoniae, 2 P.aeruginosa, 1 H.influenzae, 1 S.aureus, 1 mixed S. aureus and K.pneumoniae, and 1 E.coli and Grp.D Streptococcus. All of the patients evaluated were judged to be improved or cured. Levofloxacin is an additional option as monotherapy for the treatment of CAP.
Nicodemo
A C
AC
Division of Infectious Diseases, Clinical Hospital of the University of Sã Paulo Medical School, São Paulo, SP, Brazil. acnicode@zip.net.com.br
Lima Nicodemo
E
E
Idrahim
K Y
KY
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D017714:Community-Acquired Infections / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D064704:Levofloxacin; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000209:etiology
D000890:Anti-Infective Agents; D064704:Levofloxacin; D015242:Ofloxacin